Clinical Trials Highlight – ADJUST-T1D Trial at Oregon Health & Science University


Are You Interested in Participating in a Research Study at OHSU to Learn More about the Potential of Semaglutide (brand name Ozempic) as a Treatment for Type 1 Diabetes?

Currently, the standard of care for treatment of Type 1 Diabetes is insulin.  However, there is increasing recognition that insulin is not sufficient to address the full metabolic impact of T1D.  As a result, JDRF is helping to fund studies looking at combination therapy.

One such study, the ADJUST-T1D Trial, is currently enrolling in our chapter through Oregon Health and Science University (OHSU).  This trial will look at the use of Semaglutide (brand name Ozempic) as a treatment for Type 1 Diabetes in obese adults.  It is being funded by JDRF and Novo Nordisk.

Semaglutide is a class of medications called GLP-1 agonists. GLP-1 agonists are currently used in the treatment of Type 2 Diabetes to help control appetite, increase the release of insulin from the pancreas, suppress glucagon secretion, and slow the rate at which food leaves the stomach.  In people with T2D, GLP-1 agonists like Semaglutide also have been shown to cause weight loss and have a beneficial effect on the heart.



The purpose of this study is to assess the use of once weekly Semaglutide injection in overweight adults with type 1 diabetes (T1D), who are using FDA-approved hybrid closed-loop therapies but remain inadequately controlled.

Inclusion Criteria

You may be eligible to participate if you are:

  • Diagnosed with type 1 diabetes for at least 12 months
  • Between the ages of 18 and 60 years
  • Using the T:slim X2 pump, Omnipod 5, Medtronic 670G or 770G for at least 3 months
  • HbA1c 7.0% – 10.0% at time of screening
  • Body mass index (BMI) ≥ 30 kg/

What Is Involved?

  • The study consists of 6 clinic visits and 3 phone visits.
  • You will continue to use your hybrid closed loop system as usual.
  • In addition, you will be randomized to receive once weekly injections of either Semaglutide or a placebo for 26 weeks.
  • You will receive a physical exam and have some blood drawn during the clinic visits.
  • We will also download your pump and continuous glucose monitor (CGM) data.
  • At two of the clinic visits, you will be asked to complete several cardiovascular disease assessment procedures, such as a cardiac MRI.
  • Compensation for participation in all study visits and assessments is up to $925.

Contact Information

To discuss this study or find out if you’re eligible, please contact our study staff by phone, email or scan the QR code for more information.


Oregon Health and Science University | Portland, Oregon

Phone: 503-494-4704



OHSU IRB#: 25175